Figure 6
G4-binding ligand 360A rescues TRF2 mediated p21 suppression. (A,B) TRF2 mediated p21 repression is rescued by G4-binding ligands. A combination treatment with Doxorubicin and intracellular G4-ligand 360A rescues p21 activation relative to Doxorubicin or 360A treatment alone in HT1080 (A), *p value < 0.05, Student’s t-test; data represented as mean ± SEM of three replicates) and MDA-MB-231 cells (B), data represented as mean ± SEM, for three replicates) (GAPDH used as internal control for real-time PCR). (C) Relative loss in activation of p21 expression in cells over-expressing TRF2 relative to vector control cells was also observed by immunofluorescence in HT1080 cells on treatment with DMSO, and doxorubicin (first two panels). Treatment with 360A along with doxorubicin increased p21 activation (rightmost panel) (scale bar = 5 μm). (D,E) Increase in cells in G2/M phase in Doxorubicin + 360A combination treatment relative to treatment with Doxorubicin or 360A alone was observed (*p value < 0.05, Student’s t-test; data represented as mean ± SEM of three replicates). (F) Enhanced cytotoxic effect on cancer cells was seen with a combined treatment of Doxorubicin + 360A relative to treatment with Doxorubicin or 360A alone.
